Systemic treatment and ctDNA monitoring with K4Care for people with metastatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, longitudinal, non-interventional cohort of patients with pathologically and radiologically confirmed metastatic (stage IV) solid tumors who previously underwent K4Care tumor sequencing. Participants will provide blood samples and clinical data between March 2025 and March 2026 while receiving usual systemic therapy, and circulating tumor DNA (ctDNA) levels will be measured from plasma cfDNA. The study will relate changes in ctDNA and mutation allele fraction to clinical outcomes such as progression-free survival and overall survival. Data are collected in a real-world clinical setting at the Medical Genetics Institute in Ho Chi Minh City using prior K4Care sequencing results to link tissue mutations with plasma signals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pathological and imaging confirmation of metastatic or progressive stage IV cancer.
* Consent to the use of their clinical data.
* Diagnosis of one of the following common solid tumor types: lung, colorectal, breast, gastric, or cancer of unknown primary origin.
* Prior K4Care testing to identify tumor tissue (FFPE) mutations and consent to the use of their sequencing data.

Exclusion Criteria:

* Refusal to participate in the study.
* Absence of prior K4Care testing.
* Diagnosis of early-stage cancer or hematologic malignancy.
* Refusal to provide clinical information or blood samples.

Where it's running

• Medical Genetics Institute
  Ho Chi Minh City, Hồ Chí Minh, Vietnam Recruiting

Study contacts

• Study coordinator: Sinh D Nguyen, PhD. MD
• Email: sinhnguyen@genesolutions.vn
• Phone: +84 834105425

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• e-Motion: Promoting Emotion Regulation for People Living with Chronic Cancer

  This pilot tests two emotion-regulation programs—a guided self-help program and a combined group plus guided self-help program—for people recently diagnosed with metastatic or other chronic cancers.

  Recruiting Université Libre de Bruxelles · Brussels, Anderlecht and 1 other locations · NCT07236021

• Investigating REC-1245 for advanced or metastatic cancer

  This study is testing a new oral medication called REC-1245 to see if it can help people with advanced or metastatic cancer who haven't responded well to standard treatments.

  Recruiting at 6 sites Phase 1/2 Recursion Pharmaceuticals Inc. · Duarte, California and 6 other locations · NCT06678659

• Combining therapy to reduce cancer-related fatigue in metastatic cancer patients

  This study is testing if combining therapy with a placebo can help reduce fatigue in people with metastatic cancer.

  Recruiting Phase 2/3 M.D. Anderson Cancer Center · Houston, Texas · NCT06085716

• Personalized cancer treatment based on genomic analysis

  This study is testing whether personalized cancer treatments based on each patient's unique genetic makeup can improve outcomes for people with advanced cancers.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT02155621

• Antibody-drug conjugates for first- and second-line treatment of metastatic HER2‑negative and triple‑negative breast cancer

  This prospective registry will collect real-world data to see how FDA-approved antibody-drug conjugates work as first- or second-line treatments for adults with metastatic HER2‑negative or triple-negative breast cancer.

  Recruiting at 3 sites University of California, San Francisco · San Francisco, California and 2 other locations · NCT06774027

• Combining Selinexor and Talazoparib for Advanced Triple Negative Breast Cancer

  This study is testing a combination of two drugs, Selinexor and Talazoparib, to see if they can help people with advanced triple negative breast cancer.

  Recruiting Phase 1/2 National University Hospital, Singapore · Singapore · NCT05035745

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.